NewAmsterdam Pharma Company NAMS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $22.57M-52.1% | $22.5M-50.6% | $35.24M+4.9% | $64.01M+762% | $47.14M+587% | ||
| $135.09M-12.1% | $141.83M-6.3% | $138.13M-12.5% | $142.86M-13.7% | $153.73M-4.8% | ||
| $102.65M+23.5% | $106.35M+51.0% | $100.04M+66.9% | $93.93M+85.5% | $83.15M+88.9% | ||
| $237.74M+0.4% | $248.19M+11.9% | $238.18M+9.4% | $236.8M+9.6% | $236.87M+15.3% | ||
| $237.74M+0.4% | $248.19M+11.9% | $238.18M+9.4% | $236.8M+9.6% | $236.87M+15.3% | ||
| -$215.18M-13.4% | -$225.68M-28.0% | -$202.93M-10.2% | -$172.79M+17.2% | -$189.73M+4.5% | ||
| -953.6%-551pp | -1,002.9%-616pp | -575.8%-27.7pp | -270%+2,541pp | -402.5%+2,492pp | ||
| $25.89M+22.4% | $27.59M+63.5% | $25.6M+70.0% | $23.33M+70.6% | $21.15M+57.6% | ||
| $7.23M+6,299% | $13.14M+299% | $5.27M-18.8% | $9.73M+821% | $113K+126% | ||
| -$212.73M-13.5% | -$203.82M+15.6% | -$221.07M-11.2% | -$165.72M+27.8% | -$187.36M+18.1% | ||
| —— | —— | —— | —— | —— | ||
| -$212.73M-13.5% | -$203.82M+15.6% | -$221.07M-11.1% | -$165.72M+27.8% | -$187.36M+18.1% | ||
| -942.8%-545pp | -905.7%-375pp | -627.3%-35.2pp | -258.9%+2,831pp | -397.5%+2,935pp | ||
| -$1.79+4.8% | -$1.73+33.5% | -$2.05+8.9% | -$1.62+38.6% | -$1.88+30.4% | ||
| -$1.79+4.8% | -$1.73+33.5% | -$2.05+8.9% | -$1.62+38.6% | -$1.88+30.4% | ||
| —— | —— | —— | —— | $24.32M+173% | ||
| $30.6M+664% | $22.78M-41.0% | $27.02M+25.6% | -$1.42M-105% | -$5.43M-114% | ||
| -$212.95M-13.7% | -$203.49M+15.8% | -$220.86M-11.0% | -$165.81M+27.7% | -$187.35M+18.1% | ||
| $7.23M+6,299% | $13.14M+299% | $5.27M-18.8% | $9.73M+821% | $113K+126% | ||
| —— | —— | —— | —— | —— | ||
| -$213K-28,500% | $326K+624% | $184.25K— | -$117.5K— | $750— | ||
| $22.57M-52.1% | $22.5M-50.6% | $35.24M+4.9% | $64.01M+762% | $47.14M+587% | ||
| -$215.18M-13.4% | -$225.68M-28.0% | -$202.93M-10.2% | -$172.79M+17.2% | -$189.73M+4.5% | ||
| -$214.95M-13.4% | -$225.46M-28.0% | -$202.72M-10.1% | -$172.62M+17.3% | -$189.58M+4.5% | ||
| -$214.95M-13.4% | -$225.46M-28.0% | -$202.72M-10.1% | -$172.62M+17.3% | -$189.58M+4.5% | ||
| -952.6%-550pp | -1,001.9%-615pp | -575.2%-27.3pp | -269.7%+2,540pp | -402.2%+2,491pp | ||
| -$215.18M-13.4% | -$225.68M-28.0% | -$202.93M-10.2% | -$172.79M+17.2% | -$189.73M+4.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does NewAmsterdam Pharma Company's income statement data come from?
- Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.